CA2317416A1 - Substituted 1,2,4-triazolo[3,4-a]pyridazine - Google Patents
Substituted 1,2,4-triazolo[3,4-a]pyridazine Download PDFInfo
- Publication number
- CA2317416A1 CA2317416A1 CA002317416A CA2317416A CA2317416A1 CA 2317416 A1 CA2317416 A1 CA 2317416A1 CA 002317416 A CA002317416 A CA 002317416A CA 2317416 A CA2317416 A CA 2317416A CA 2317416 A1 CA2317416 A1 CA 2317416A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- triazolo
- triazol
- cognition
- chz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 14
- 230000019771 cognition Effects 0.000 claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 25
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- NZMJFRXKGUCYNP-UHFFFAOYSA-N α5ia Chemical compound O1C(C)=CC(C=2N3N=C(OCC=4N=NN(C)C=4)C4=CC=CC=C4C3=NN=2)=N1 NZMJFRXKGUCYNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000003292 diminished effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 25
- CBHTTYDJRXOHHL-UHFFFAOYSA-N 2h-triazolo[4,5-c]pyridazine Chemical class N1=NC=CC2=C1N=NN2 CBHTTYDJRXOHHL-UHFFFAOYSA-N 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 20
- 239000000243 solution Substances 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 206010012289 Dementia Diseases 0.000 description 11
- 238000000524 positive electrospray ionisation mass spectrometry Methods 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- 206010012218 Delirium Diseases 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000012131 assay buffer Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000031091 Amnestic disease Diseases 0.000 description 3
- 206010012239 Delusion Diseases 0.000 description 3
- 206010012374 Depressed mood Diseases 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 231100000868 delusion Toxicity 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 3
- -1 sorbitoi Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
- SYOANZBNGDEJFH-UHFFFAOYSA-N 2,5-dihydro-1h-triazole Chemical compound C1NNN=C1 SYOANZBNGDEJFH-UHFFFAOYSA-N 0.000 description 2
- OJVAMHKKJGICOG-UHFFFAOYSA-N 2,5-hexanedione Chemical compound CC(=O)CCC(C)=O OJVAMHKKJGICOG-UHFFFAOYSA-N 0.000 description 2
- BNMPIJWVMVNSRD-UHFFFAOYSA-N 5-methyl-1,2-oxazole-3-carboxylic acid Chemical compound CC1=CC(C(O)=O)=NO1 BNMPIJWVMVNSRD-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 229960004381 flumazenil Drugs 0.000 description 2
- 229960002200 flunitrazepam Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005567 liquid scintillation counting Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- UQTJGZYAFKMABR-UHFFFAOYSA-N (4-chlorophthalazin-1-yl)hydrazine Chemical compound C1=CC=C2C(NN)=NN=C(Cl)C2=C1 UQTJGZYAFKMABR-UHFFFAOYSA-N 0.000 description 1
- XDDGKNRSCDEWBR-UHFFFAOYSA-N (6-bromopyridin-2-yl)methanol Chemical compound OCC1=CC=CC(Br)=N1 XDDGKNRSCDEWBR-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ODCNAEMHGMYADO-UHFFFAOYSA-N 1,4-dichlorophthalazine Chemical compound C1=CC=C2C(Cl)=NN=C(Cl)C2=C1 ODCNAEMHGMYADO-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical compound CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 1
- RYPJWVSUBZEZRG-UHFFFAOYSA-N 3-methoxy-[1,2,4]triazolo[3,4-a]phthalazine Chemical compound C1=CC=C2C=NN3C(OC)=NN=C3C2=C1 RYPJWVSUBZEZRG-UHFFFAOYSA-N 0.000 description 1
- CUMCMYMKECWGHO-UHFFFAOYSA-N 3-methyl-1,2-oxazole Chemical compound CC=1C=CON=1 CUMCMYMKECWGHO-UHFFFAOYSA-N 0.000 description 1
- SPKCNMWPMHLVKI-UHFFFAOYSA-N 5-methyl-3-[6-(2h-triazol-4-ylmethoxy)-[1,2,4]triazolo[3,4-a]phthalazin-3-yl]-1,2-oxazole Chemical compound O1C(C)=CC(C=2N3N=C(OCC=4NN=NC=4)C4=CC=CC=C4C3=NN=2)=N1 SPKCNMWPMHLVKI-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- 102000027484 GABAA receptors Human genes 0.000 description 1
- 108091008681 GABAA receptors Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 238000012347 Morris Water Maze Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 231100000643 Substance intoxication Toxicity 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- ZEKANFGSDXODPD-UHFFFAOYSA-N glyphosate-isopropylammonium Chemical compound CC(C)N.OC(=O)CNCP(O)(O)=O ZEKANFGSDXODPD-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000216 proconvulsive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- SHNUBALDGXWUJI-UHFFFAOYSA-N pyridin-2-ylmethanol Chemical compound OCC1=CC=CC=N1 SHNUBALDGXWUJI-UHFFFAOYSA-N 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 208000018726 traumatic encephalopathy Diseases 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- RZLMQJSSMROKSS-UHFFFAOYSA-N trimethyl-[2-(triazol-1-ylmethoxy)ethyl]silane Chemical compound C[Si](C)(C)CCOCN1C=CN=N1 RZLMQJSSMROKSS-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A substituted triazolopyridazine derivative, its use in cognition enhancement therapy, compositions containing it and processes for its manufacture are disclosed.
Description
SUBSTITUTED 1.2.4-TRIAZOLO(3.4-aIPYRIDAZINE
The present invention relates to a substituted triazolo-pyridazine derivative, to its use in therapy, to compositions containing it and to a process for its manufacture.
We have now discovered that it is possible to obtain medicaments which have cognition enhancing effects which may be employed with less risk of proconvulsant effects previously described with benzodiazepine receptor partial or full inverse agonists. Inverse agonists which are inverse agonists for the a5 receptor and are relatively free of activity at al, a2 and a3 receptor binding sites are preferred.
European Patent Applications 0085840 and 0134946 describe related series of 1;2,4-triazolo[3,4-a]phthalazine derivatives which are stated to possess antianxiety activity. However, there is no disclosure nor any suggestion in either of these publications of the compounds of the present invention, nor that the compounds disclosed in the Applications have any cognition enhancing properties.
The present invention provides a compound which is:
3-(5-methylisoxazol-3-yl)-6-( 1-methyl-1, 2, 3-triazol-4-yl)methyloxy-1, 2, 4-triazolo[3,4-a]phthalazine.
Cognition enhancement can be shown by testing the compound in the Morris watermaze as reported by McNamara and Skelton, Psychobiology, 21:101-108. The functional efficacy at the various receptor subtypes can be calculated using the method disclosed in WO-A-9625948.
Thus, for example, the compound of the present invention can be used in a variety of disorders of the central neiwous system. Such disorders include delirium, dementia and amnestic and other cognitive disorders. Examples of delirium are delirium due to substance intoxication or substance withdrawal, delirium due to multiple etiologies and delirium NOS (not otherwise specified).
Examples of dementia are: dementia of the Alzheimer's type with early onset -which can be uncomplicated or with delirium, delusions or depressed mood;
dementia of the Alzheimer's type, with late onset, which can be uncomplicated or with delirium, delusions or depressed mood; vascular dementia which can be uncomplicated or with delirium, delusions or depressed mood; dementia due to WO 99/43677 . 2 - PCT/GB99/00485 HIV disease; dementia due to head trauma; dementia due to Parkinson's disease;
dementia due to Huntington's disease; dementia due to Pick's disease; dementia .
due to Creutzfeld-Jakoh disease; dementia which is substance-induced persisting or due to multiple etiologies; and dementia NOS. Examples of amnestic disorders are amnestic disorder due to a particular medical condition or which is substance-induced persisting or which is amnestic disorder NOS.
The invention also provides pharmaceutical compositions comprising the compound of this invention and a pharmaceutically acceptable carrier.
Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, transdermal patches, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufffation. For preparing solid compositions such as tablets, the principal active ingredient is I5 mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitoi, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums or surfactants such as sorbitan monooleate, polyethylene glycel, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of the compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. Typical unit dosage forms contain from 1 to 100 mg, for example 1, 2, 5, 10, 25, 50 or mg, of the active ingredient. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A
variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric.
acids with such materials as shellac, cetyl alcohol and cellulose acetate.
The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oiI suspensions, and flavoured emulsions with edible oils such as cottonseed oii, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrroiidone or gelatin.
The present invention further provides the use of the compound of the present invention in the manufacture of a medicament for the enhancement of cognition, preferably in a human suffering from a dementing illness such as Alzheimer's disease.
For the enhancement of cognition, a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.01 to 100 mg/kg per day, and especially about 0.01 to 5 mglkg of body weight per day. The compound may be administered on a regimen of 1 to 4 times per day. In some cases, however, dosage outside these limits may be used.
It is preferred that the compound of the present invention be ground, for example using a pestle and mortar or industrial equivalent thereto, to a particle size of between 1 and 10 ~,M, and preferably less than 5 uM, before formulation.
The compound may be micronised or sonicised by methods known in the art or nanonised, for example by methods disclosed in US-A-5145684.
The present invention also provides a process for the production of the compound of the present invention, which comprises reacting a methylating reagent, such as- lithium hexamethyldisilazide with 3-(5-methylisoxazol-3-yl}-( 1H-1, 2, 3-triazol-5-yl) methyloxy-1, 2, 4-triazolo [3, 4-a] phthalazine.
The reaction is generally carried out in a solvent such as DMF, generally at a temperature below 0°C with warming to about room temperature and generally under an inert gas such as nitrogen. The reaction mixture is generally allowed to stand for 4-12 hours. The desired product is generally purified from other reaction products by a conventional separation technique such as preparative HPLC.
During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W.
McOmie, Plenum Press, 19'73; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from IO the art.
The compound in accordance with this invention potently inhibit the binding of [3H]-ffumazenil to the benzodiazepine binding site of human GABAn receptors containing the a5 subunit stably expressed in Ltk- cells.
Reagents ~ Phosphate buffered saline (PBS).
~ Assay buffer: 10 mM KHzP04, 100 mM KCI, pH 7.4 at room temperature.
~ [3HJ-Flumazenil (18 nM for al[i3y2 cells; 18 nM for a2[33y2 cells; 10 nM for a3[33y2 cells; 10 nM for a5(33y2 cells) in assay buffer.
~ Flunitrazepam 100 uM in assay buffer.
~ Cells resuspended in assay buffer (1 tray to 10 ml).
Harvesting Cells Supernatant is removed from cells. PBS (approximately 20 ml) is added.
The cells are scraped and placed in a 50 ml centrifuge tube. The procedure is repeated with a further 10 ml of PBS to ensure that most of the cells are removed. The cells are pelleted by centrifuging for 20 min at 3000 rpm in a benchtop centrifuge, and then frozen if desired. The pellets are resuspended in 10 ml of buffer per tray (25 cm x 25 cm) of cells.
Assay Can be carried out in deep 96-well plates or in tubes. Each tube contains:
~ 300 ~1 of assay buffer.
~ 50 N.1 of [3H]-flumazenil (final concentration for al[i3y2: 1.8 nM; for a2[33y2: 1.8 nM; for a3(33y2: 1.0 nM; for a5(33y2: 1.0 nM).
WO 99/43677 _ 5 - PCT/GB99/00485 ~ 50 ul of buffer or solvent carrier (e.g. IO% DMSO) if compound is dissolved in 10% DMSO (total); test compound or flunitrazepam (to determine non-specific binding), 10 p,M final concentration.
~ 100 pl of cells.
Assays are incubated for 1 hour at 40°C, then filtered using either a Tomtec or Brandel cell harvester onto GFB filters followed by 3 x 3 ml washes with ice cold assay buffer. Filters are dried and counted by liquid scintillation counting. Expected values for total binding are 3000-4000 dpm for total counts and less than 200 dpm for non-specific binding if using liquid scintillation counting, or 1500-2000 dpm for total counts and less than 200 dpm for non-specific binding if counting with meltilex solid scintillant. Binding parameters are determined by non-linear Least squares regression analysis, from which the inhibition constant K. can be calculated for the test compound.
The compound in accordance with this invention potently inhibits the I5 binding of [3H]-ffumazenil to the benzodiazepine binding site of human GABAA
receptors containing the a5 subunit stably expressed in Ltk- cells.
The compound of the accompanying Example was tested in the above assay, and was found to possess a K; value for displacement of j3H]Ro 15-1788 from the a5 subunit of the human GABAn receptor of 100 nM or less.
The compound of the present invention has been shown to enhance cognition in the rat water maze test (Morris, Learning and Motivation, 1981, 12, 239ffj. Further details of methodology for demonstrating that the present compounds enhance cognition can be found in WO-A-9625948. This has been demonstrated at a minimum effective dose of 0.3mg/kg at which the compound of the present invention has 40% receptor occupancy. It has also been demonstrated at a dose of 3mglkg.
The compound of the present invention can be made as described in following Examples. Precise details of the reaction conditions, and obvious modifications of the reaction procedure, are well within the capabilities of the skilled person.
6-Chloro-3-(5-Methvlisoxazol-3-vD-1 2 4-triazolof3 4 a]nhthalazine -, _ a) 1-Chloro-4-hvdrazinophthalazine 1,4-Dichlorophthalazine (20.Og, 0.100 mol) was added to a boiling solution of hydrazine monohydrate (37.3 ml, 0.765 mol) in ethanol (500 ml) and the mixture heated at reflux for 0.5 h. The mixture was cooled to room temperature and the solid collected by filtration and washed with ether. The material was taken with n-butanol and ammonia solution (sp. gr. 0.91) and heated until the solid dissolved. The organic layer was separated, evaporated in vacuo and the residue azeotroped with xylene (x2) and dried in vacuo to give the title-hydrazine (11.5 g, 59°/), 3H NMR (250 MHz, døDMSO) 8 7.84 - 8.04 (3H, m, Ar-H}, 8.20 (1H, m, Ar-H); MS (ES+) m/e 194 [MH]+.
b) 5-Methvlisoxazole-3-carboxvlic acid A mixture of acetonylacetone (lOg, 88 mmol) and nitric acid (sp. gr. 1.42) /
water (2:3) (50 ml) was cautiously brought to reflux under a stream of nitrogen and boiled for lh. The solution was cooled to room temperature and aged overnight. The resultant solid was collected by filtration, washed with chilled water (2 x 7 ml) and hexane, and dried in vacuo to give the title-acid (4.4g, 40%), 1H NMR (CDCIs) b 2.50 (3H, d, J=0.8Hz, Me), 6.41 (1H, d, J=0.8Hz, Ar-H).
c) 6-Chloro-3-(5-Methvlisoxazol-3-vb-1 2 4-triazolof3 4 ainhthalazine 5-Methylisoxazole-3-carboxylic acid (5.24 g, 41.3 mmol), bis(2-oxo-3-oxazolidinyl)phosphinic chloride (10.5 g, 41.2 mmol) and triethylamine (lL5 ml, 82.5 mmol) were added successively to a stirred suspension of 1-chloro-4-hydrazinophthalazine (8.00 g, 41.2 mmol) in dichloromethane (11) at 0 °C under nitrogen. The mixture was stirred at 0 °C for 2h and at room temperature overnight. The solvent was evaporated in vacuo, the residue triturated with water and the solid filtered off, washed with hexane and dried in uacuo to give the ketohydrazine (11 g), MS (ES+) m/e 304 [MH]+. A solution of the ketohydrazine (11 g) and triethylamine hydrochloride (2.2 g, 20% w/w) in xylene 30, (500 ml) was heated at reflux for 3 h. The mixture was cooled to room -temperature and the solvent evaporated in uacuo. The residue was dissolved in dichloromethane, washed with water (x 2), dried (MgS04) and evaporated in vacuo, and the solid recrystallised (dichloromethane/hexane) to give the title-compound (6.8 g, 58%), 1H NMR (360MHz, CDCl3) 8 2.59 (3H, s, Me), 6.90 (1H, s, Ar-H), 7.95 (1H, m, A.r-H), 8.0? (1H, m, Ar-H), 8.34 (1H, m, Ar-H), 8.78.(1H, s, Ar-H); MS (ES+) m/e 286 [MHJ+.
REFERENCE El AMPLE 1 3-(5-Methvlisoxazol-3-vl)-6-(2-nvridyDmethyloxy 1 2 4 triazoloj3 4 aJphthalazine Sodium hydride (244 mg of a 60% dispersion in oil, 6.10 mmol) was added to a stirred solution of 2-pyridylcarbinol (470 mg, 4.27 mmol) in DMF (60 ml) at room temperature under nitrogen and the mixture stirred for 0.25 h. After this time, Intermediate 1 (1160 mg, 4.07 mmol) was added and the mixture stirred for 2h. The solvent was removed in uacuo and the residue dissolved in dichloromethane, washed with water (x2), dried (MgSOa) and evaporated in vacuo. Flash chromatography on silica gel eluting with 3%
methanol/dichloromethane followed by recrystallisation (dichloromethane/hexane) gave the title-product (640 mg, 44%), mp 234 - 236 °C;
'H NMR (360MHz, CDCIs) b 2.59 (3H, d, J =0.8Hz, Me), 5.77 (2H, s, CHz), 6.82 (1H, d, J=0.8Hz, A.r-H), 7.30 (1H, m, Ar-H), 7.74 - 7.85 (3H, m, Ar-H); 7.95 (1H, m, Ar-H), 8.33 (1H, d, J=7.8Hz, Ar-H), 8.64 - 8.72 (2H, m, Ar-H}; MS (ES+) m/e 359 [MHJ+; Anal. Found. C, 62.93; H, 3.56; N, 22.94. CisHi4NsOz 0.05 (CHzCIz) requires C, 63.10; H, 3.92; N, 23.1?%.
6-(6-Bromonvridin-2-vDmethvioxv 3 l5 methvlisoxazol 3 vl) 1 2 4 triazolo(3 4 a] phthalazine The title-compound was prepared from Intermediate 1 and 2-bromopyridine-6-methanol (Tetrahedron Lett., 1996, 50, 2537) following the procedure given for Reference Example I. The product was isolated by addition of water to the reaction mixture and the resulting precipitate was filtered off.
Flash chromatography on silica gel, eluting with ethyl acetate, and recrystallisation (ethyl acetate-methanol) gave the title phthalaxine, mp 247.5 -249 °C; 'H NMR (360 MHz, CDCIs) 8 2.61 (3H, d, J = 0.7 Hz, Me), 5.?3 (2H, s, CHz), 6.82 (1H, d, J = 0.7 Hz, Ar-H), 7.48 (1H, d, J = 7.8 Hz, Ar-H), 7.63 (1H, t, J = 7.7 Hz, Ar-H), ?.76 (1H, d, J = 7.4 Hz, Ar-H), 7.84 (1H, t, J = 8.4 Hz, Ar-H), 7.98 (IH, t, J = 8.4 Hz, Ar-H), 8.31 (1H, d, J = 8.5 Hz, Ar-H), 8.70 (1H, d, Ar-H);
MS (ES+) m/e 437, [MH]+; Anal. Found C, 52.27; H, 2.85; N, 19.14. C19H~3N6O2 -Br. 0.1 (Hz0) requires C, 51.98; H, 3.03; N, 18:60%.
6-Hvdroxv-3-(5-Methvlisoxazol-3-vl)-1 2 4 triazolof3 4 alnhthalaz_ine A solution of sodium hydroxide (0.67 g, I7 mmol) in water (7.5 ml) was added to a stirred solution of Intermediate 1 (1.0 g, 3.5 mmol) in dioxane (37.5 ml) and the mixture heated at reflux for 4 h. The solvent was evaporated in uacuo and the residue partitioned between water and diethyl ether. The aqueous layer was separated, washed with ether (x 1) and then acidified with hydrochloric acid until pH2 was attained. The solid which precipitated out of solution was filtered off and the aqueous filtrate extracted with dichloromethane (x 3). The combined extracts were dried (MgS04) and evaporated in udcuo and combined with the precipitate to give the title product (0.45 g, 48%), 1H NMR
(250 MHz, ds-DMSO) 8 2.58 (3H, d, J = 0.7 Hz, Me), 7.07 (1H, d, J = 0.9 Hz, Ar-H), 7.94 (1H, m, Ar-H), 8.08 (1H, m, Ar-H), 8.24 (1H, d, J = 7.4 Hz, Ar-H), 8.54 (1H, d, J = 7:4 Hz, Ar-H), 13.32 (1H, br s, NH); MS (ES+) mle 268 [MH]+
3-(5-Methvlisoxazol-3-vl)-6-(1H-1 2 3-triazol 5 vDmethyloxy 1 2 4 triazolo f 3.4-alphthalazine a) 5-Formvl-I-f2-(trimethvlsilvbethoxvlmethvl 1 2 3 triazole n-Butyl lithium (6.8m1 of a 1.6M solution in hexanes, 10.9mmo1) was added dropwise over 0.08h to a stirred solution of 1-[2-(trimethyl-silyl)ethoxy]methyl-1,2,3-triazole (J. Heterocycl. Chem., 1992, 29, 1203) (2.077g, 10.42mmo1) in THF (30m1) at -78°C under nitrogen. The solution was allowed to warm to -60°C aver 0.67h, then retooled to -78°C and DMF (0.9m1, 11.6mmo1) added. The mixture was allowed to warm to room temperature and stirred for 16.5h. Saturated ammonium chloride solution (50m1) was added and the _ reaction mixture extracted with diethyl ether (3 x 80m1). The combined ethereal extrants were dried (MgS04), evaporated in uacuo, and the residue chromatographed on silica gel, eluting with 30% ethyl acetate/hexane, to give the WO 99/43677 - 9 _ PCT/GB99/00485 title-triaxole (1.7138, 72%), 1H NMR (360 MHz, CDCIs) 8 0.01 (9H, s, MesSi), 0.92-0.99 (2H, m, CHz), 3.64-3.69 (2H, m, CHz), 6.05 (2H, s, CHa), 8.31 (lH;.s;
Ar-H), 10.12 (1H, s, CHO).
b) 5-Hvdroxvmethvl-1-f2-(trimethvlsilvDethoxvlrnethyl 1 2 3 triazole Sodium borohydride (0.2848, 7.51mmo1) was added to a stirred solution of the preceding triazole (1.7048, 7.495mmol) in methanol (8ml} at 0°C
under nitrogen. The mixture was stirred at 0°C for 0.5h and at room temperature for O.Sh. Water was added and the mixture partitioned between dichloromethane and saturated brine. The aqueous layer was separated and further extracted with dichloromethane (x2). The combined organic layers were dried ((MgS09) and evaporated in uacuo and the residue chromatographed on silica gel, eluting with ?0% ethyl acetate/hexane, to give the title product (1.348, 78%), 1H NMR
(360 MHz, CDCla) 8 0.00 (9H, s, MesSi), 0.90-0.95 (2H, m, CHz), 3.58-3.63 (2H, m, CHz), 4.84 (2H, s, CHz), 5.80 (2H, s, CHz), 7.68 (1H, s, Ar-H).
c) 3-(5-Methvlisoxazol-3-vl)-6-11-f2-(trimethvlsilvDethoxvlmethvl 1 2 3 triazol-5-vllmethvloxv-12 4-triazolof3 4 a]'~n~hthalazine The title-compound was prepared from Intermediate 1 and the preceding alcohol following the procedure described for Example 10, 360 MHz (360 MHz, CDCIs) 8 0.00 (9H, s, MesSi), 0.88-0.93 (2H, m, CHz), 2.63 (3H, s, Me), 3.61-3.66 (2H, m, CHz), 5.92 (2H, s, CHz), 5.97 (2H, s, CHz), 6.89 (1H, s, Ar-H), 7.86 (1H, m, Ar-H), 8.02 (1H, t, J = 7.7 Hz, Ar-H), 8.18 (1H, s, Ar-H), 8.23 (1H, d, J =
8.0 Hz, Ar-H), 8.76 (1H, d, J = 8.0 Hz, Ar-H); MS (ES+) m/e 479 [MH]+.
d) 3-(5-Methvlisoxazol-3-vl)-6-(1H 1 2 3 triazol 5 vbmethyloxv 1 2 4 triazolof3 4-a]nhthalazine A mixture of the preceding product, ethanol (lOml) and 2N HCl (20m1) was heated at 50°C for 15.25h. The solution was basified to pH 12 with saturated sodium carbonate solution and the solvents evaporated in uacuo. The residue was azeotroped with ethanol (x2) and chromatographed on silica gel, eluting with 0-4% methanol/dichloromethane (gradient elution), to give the title product, IH NMR (400 MHz, CDCIs) 8 2.65 (3H, s, Me), 5.73 (2H, s, CHz), 7.02 (1H, s, Ar-H), 7.87 (1H, t, J = 7.8 Hz, Ar-H), 7.99-8.03 (2H, m, 2 of Ar-H), 8.24 (1H, d, J = 8.2 Hz, Ar-H) 8.72 (1H, d, J = 7.9 Hz, Ar-H); MS (ES+) m/e ~~+.
WO 99/43677 - 10 - PCTlGB99/00485 3-(5-Methvlisoxazol-3-vl)-6-ll-methyl-1 2 3 triazol 5 vl)methyloxy 1 2 4 triazolof3 4-alnhthalazine 3-(5-methvlieoxazol 3 vl) 6 (2 methyl 1 2 3 triazol yDmethyloxv-1 2 4-triazolof3 4-alnhthalazine and 3 (5 methylisoxazol 3 vl) 6 (1 methyl-1.2,3-triazol-4-vDmethvloxv-I 2 4-triazolof3 4 aln~hthalazine Lithium hexamethyldisilazide (1.63m1 of a 1M solution in THF, 1.63mmol) was added dropwise to a stirred solution of 3-(5-methylisoxazol-3-yl)-6-(1H-1,2,3-triazol-5-yl)methyloxy-1,2,4-triazolo[3,4-a]phthalazine (241mg, 0.626mmo1) prepared as in Reference Example 3 in DMF (50m1) at -31°C
under nitrogen. The mixture was warmed to -23°C over 1.5h, methyl iodide (O.lOml, l.6mmo1) added dropwise and the reaction mixture allowed to warm to room temperature overnight. Water was added and the solvent evaporated in vacuo.
The residue was partitioned between dichloromethane and water and the aqueous phase separated and re-extracted with dichloromethane (xl). The combined organic extrants were washed with brine (xl), dried (MgS04) and evaporated in vacuo . Chromatography of the residue on silica gel, eluting with 0-5% methanol/dichloromethane (gradient elution), followed by preparative HPLC (YMC Sil column, 250 x 20mm) eluting with 5% methanol/1-chlorobutane, separated the triazole isomers:
Least polar isomer (HPLC solvent system): 3-(5-methvlisoxazol-3-yD-6-(2-methvl-12 3-triazol-4-vl)methvloxv 12 4 triazolo[3 4 a]phthalazine 1H NMR
(400 MHz, CDCIa) 8 2.59 (3H, s, Me), 4.21 (3H, s, Me), 5.73 (2H, s, CHz), 6.89 (1H, s, Ar-H), 7.79 (1H, m, Ar-H), 7.94 (1H, m, Ar-H), 8.10 (1H, s, Ar-H), 8.22 (1H, d, J = 8.0 Hz, Ar-H), 8.67 (1H, d, J = 8.0 Hz, Ar-H); MS (ES+) mle 363 [MH]+.
Intermediate polarity isomer: 3-l5-methvlisoxazol-3-vD-6-(1-methyl 1 2 3 triazol 4-vl)methvloxv-1 2 4-triazolof3 4-alDhthalazine 1H NMR (400MHz, CDCls) 8 2.60 (3H, s, Me), 4.09 (3H, s, Me), 5.78 (2H, s, CHz), 6.90 (1H, d, J = 0.8 Hz, Ar-H), 7.80 (1H, m, Ar-H), 7.94 (1H, m, Ar-H), 8.25 (1H, d, J = 8.0 Hz, Ar-H), 8.65 (1H, d, J = 8.0 Hz, Ar-H), 8.73 (1H, s, Ar-H); MS (ES+) mle 363 [MH]+.
Most polar isomer (HPLC solvent system): 3-(5-methvlisoxazol-3-vl)-6-(1-methv_1-1.2.3-triazol-5-vl)methvloxy-1 2 4-triazolof3 4 alnhthalazine 1H NMR (400 MHz, CDCIa) 8 2.56 (3H, s, Me), 4.19 (3H, s, Me), 5.?6 (2H, s, CHz), 6.82 (1H, s, Ar-H), 7.80 (1H, m, Ar-H), 7.96 (1H, m, Ar-H), 8.04 (1H, s, Ar-H), 8.12 (1H, d, J = 8.8 Hz, Ar-H), 8.67 (1H, d, J = 8.0 Hz, Ar-H); MS (ES+) m/e 363 [MIi]+. _ _
The present invention relates to a substituted triazolo-pyridazine derivative, to its use in therapy, to compositions containing it and to a process for its manufacture.
We have now discovered that it is possible to obtain medicaments which have cognition enhancing effects which may be employed with less risk of proconvulsant effects previously described with benzodiazepine receptor partial or full inverse agonists. Inverse agonists which are inverse agonists for the a5 receptor and are relatively free of activity at al, a2 and a3 receptor binding sites are preferred.
European Patent Applications 0085840 and 0134946 describe related series of 1;2,4-triazolo[3,4-a]phthalazine derivatives which are stated to possess antianxiety activity. However, there is no disclosure nor any suggestion in either of these publications of the compounds of the present invention, nor that the compounds disclosed in the Applications have any cognition enhancing properties.
The present invention provides a compound which is:
3-(5-methylisoxazol-3-yl)-6-( 1-methyl-1, 2, 3-triazol-4-yl)methyloxy-1, 2, 4-triazolo[3,4-a]phthalazine.
Cognition enhancement can be shown by testing the compound in the Morris watermaze as reported by McNamara and Skelton, Psychobiology, 21:101-108. The functional efficacy at the various receptor subtypes can be calculated using the method disclosed in WO-A-9625948.
Thus, for example, the compound of the present invention can be used in a variety of disorders of the central neiwous system. Such disorders include delirium, dementia and amnestic and other cognitive disorders. Examples of delirium are delirium due to substance intoxication or substance withdrawal, delirium due to multiple etiologies and delirium NOS (not otherwise specified).
Examples of dementia are: dementia of the Alzheimer's type with early onset -which can be uncomplicated or with delirium, delusions or depressed mood;
dementia of the Alzheimer's type, with late onset, which can be uncomplicated or with delirium, delusions or depressed mood; vascular dementia which can be uncomplicated or with delirium, delusions or depressed mood; dementia due to WO 99/43677 . 2 - PCT/GB99/00485 HIV disease; dementia due to head trauma; dementia due to Parkinson's disease;
dementia due to Huntington's disease; dementia due to Pick's disease; dementia .
due to Creutzfeld-Jakoh disease; dementia which is substance-induced persisting or due to multiple etiologies; and dementia NOS. Examples of amnestic disorders are amnestic disorder due to a particular medical condition or which is substance-induced persisting or which is amnestic disorder NOS.
The invention also provides pharmaceutical compositions comprising the compound of this invention and a pharmaceutically acceptable carrier.
Preferably these compositions are in unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, transdermal patches, auto-injector devices or suppositories; for oral, parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufffation. For preparing solid compositions such as tablets, the principal active ingredient is I5 mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitoi, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums or surfactants such as sorbitan monooleate, polyethylene glycel, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of the compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. Typical unit dosage forms contain from 1 to 100 mg, for example 1, 2, 5, 10, 25, 50 or mg, of the active ingredient. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A
variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric.
acids with such materials as shellac, cetyl alcohol and cellulose acetate.
The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oiI suspensions, and flavoured emulsions with edible oils such as cottonseed oii, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrroiidone or gelatin.
The present invention further provides the use of the compound of the present invention in the manufacture of a medicament for the enhancement of cognition, preferably in a human suffering from a dementing illness such as Alzheimer's disease.
For the enhancement of cognition, a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.01 to 100 mg/kg per day, and especially about 0.01 to 5 mglkg of body weight per day. The compound may be administered on a regimen of 1 to 4 times per day. In some cases, however, dosage outside these limits may be used.
It is preferred that the compound of the present invention be ground, for example using a pestle and mortar or industrial equivalent thereto, to a particle size of between 1 and 10 ~,M, and preferably less than 5 uM, before formulation.
The compound may be micronised or sonicised by methods known in the art or nanonised, for example by methods disclosed in US-A-5145684.
The present invention also provides a process for the production of the compound of the present invention, which comprises reacting a methylating reagent, such as- lithium hexamethyldisilazide with 3-(5-methylisoxazol-3-yl}-( 1H-1, 2, 3-triazol-5-yl) methyloxy-1, 2, 4-triazolo [3, 4-a] phthalazine.
The reaction is generally carried out in a solvent such as DMF, generally at a temperature below 0°C with warming to about room temperature and generally under an inert gas such as nitrogen. The reaction mixture is generally allowed to stand for 4-12 hours. The desired product is generally purified from other reaction products by a conventional separation technique such as preparative HPLC.
During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W.
McOmie, Plenum Press, 19'73; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from IO the art.
The compound in accordance with this invention potently inhibit the binding of [3H]-ffumazenil to the benzodiazepine binding site of human GABAn receptors containing the a5 subunit stably expressed in Ltk- cells.
Reagents ~ Phosphate buffered saline (PBS).
~ Assay buffer: 10 mM KHzP04, 100 mM KCI, pH 7.4 at room temperature.
~ [3HJ-Flumazenil (18 nM for al[i3y2 cells; 18 nM for a2[33y2 cells; 10 nM for a3[33y2 cells; 10 nM for a5(33y2 cells) in assay buffer.
~ Flunitrazepam 100 uM in assay buffer.
~ Cells resuspended in assay buffer (1 tray to 10 ml).
Harvesting Cells Supernatant is removed from cells. PBS (approximately 20 ml) is added.
The cells are scraped and placed in a 50 ml centrifuge tube. The procedure is repeated with a further 10 ml of PBS to ensure that most of the cells are removed. The cells are pelleted by centrifuging for 20 min at 3000 rpm in a benchtop centrifuge, and then frozen if desired. The pellets are resuspended in 10 ml of buffer per tray (25 cm x 25 cm) of cells.
Assay Can be carried out in deep 96-well plates or in tubes. Each tube contains:
~ 300 ~1 of assay buffer.
~ 50 N.1 of [3H]-flumazenil (final concentration for al[i3y2: 1.8 nM; for a2[33y2: 1.8 nM; for a3(33y2: 1.0 nM; for a5(33y2: 1.0 nM).
WO 99/43677 _ 5 - PCT/GB99/00485 ~ 50 ul of buffer or solvent carrier (e.g. IO% DMSO) if compound is dissolved in 10% DMSO (total); test compound or flunitrazepam (to determine non-specific binding), 10 p,M final concentration.
~ 100 pl of cells.
Assays are incubated for 1 hour at 40°C, then filtered using either a Tomtec or Brandel cell harvester onto GFB filters followed by 3 x 3 ml washes with ice cold assay buffer. Filters are dried and counted by liquid scintillation counting. Expected values for total binding are 3000-4000 dpm for total counts and less than 200 dpm for non-specific binding if using liquid scintillation counting, or 1500-2000 dpm for total counts and less than 200 dpm for non-specific binding if counting with meltilex solid scintillant. Binding parameters are determined by non-linear Least squares regression analysis, from which the inhibition constant K. can be calculated for the test compound.
The compound in accordance with this invention potently inhibits the I5 binding of [3H]-ffumazenil to the benzodiazepine binding site of human GABAA
receptors containing the a5 subunit stably expressed in Ltk- cells.
The compound of the accompanying Example was tested in the above assay, and was found to possess a K; value for displacement of j3H]Ro 15-1788 from the a5 subunit of the human GABAn receptor of 100 nM or less.
The compound of the present invention has been shown to enhance cognition in the rat water maze test (Morris, Learning and Motivation, 1981, 12, 239ffj. Further details of methodology for demonstrating that the present compounds enhance cognition can be found in WO-A-9625948. This has been demonstrated at a minimum effective dose of 0.3mg/kg at which the compound of the present invention has 40% receptor occupancy. It has also been demonstrated at a dose of 3mglkg.
The compound of the present invention can be made as described in following Examples. Precise details of the reaction conditions, and obvious modifications of the reaction procedure, are well within the capabilities of the skilled person.
6-Chloro-3-(5-Methvlisoxazol-3-vD-1 2 4-triazolof3 4 a]nhthalazine -, _ a) 1-Chloro-4-hvdrazinophthalazine 1,4-Dichlorophthalazine (20.Og, 0.100 mol) was added to a boiling solution of hydrazine monohydrate (37.3 ml, 0.765 mol) in ethanol (500 ml) and the mixture heated at reflux for 0.5 h. The mixture was cooled to room temperature and the solid collected by filtration and washed with ether. The material was taken with n-butanol and ammonia solution (sp. gr. 0.91) and heated until the solid dissolved. The organic layer was separated, evaporated in vacuo and the residue azeotroped with xylene (x2) and dried in vacuo to give the title-hydrazine (11.5 g, 59°/), 3H NMR (250 MHz, døDMSO) 8 7.84 - 8.04 (3H, m, Ar-H}, 8.20 (1H, m, Ar-H); MS (ES+) m/e 194 [MH]+.
b) 5-Methvlisoxazole-3-carboxvlic acid A mixture of acetonylacetone (lOg, 88 mmol) and nitric acid (sp. gr. 1.42) /
water (2:3) (50 ml) was cautiously brought to reflux under a stream of nitrogen and boiled for lh. The solution was cooled to room temperature and aged overnight. The resultant solid was collected by filtration, washed with chilled water (2 x 7 ml) and hexane, and dried in vacuo to give the title-acid (4.4g, 40%), 1H NMR (CDCIs) b 2.50 (3H, d, J=0.8Hz, Me), 6.41 (1H, d, J=0.8Hz, Ar-H).
c) 6-Chloro-3-(5-Methvlisoxazol-3-vb-1 2 4-triazolof3 4 ainhthalazine 5-Methylisoxazole-3-carboxylic acid (5.24 g, 41.3 mmol), bis(2-oxo-3-oxazolidinyl)phosphinic chloride (10.5 g, 41.2 mmol) and triethylamine (lL5 ml, 82.5 mmol) were added successively to a stirred suspension of 1-chloro-4-hydrazinophthalazine (8.00 g, 41.2 mmol) in dichloromethane (11) at 0 °C under nitrogen. The mixture was stirred at 0 °C for 2h and at room temperature overnight. The solvent was evaporated in vacuo, the residue triturated with water and the solid filtered off, washed with hexane and dried in uacuo to give the ketohydrazine (11 g), MS (ES+) m/e 304 [MH]+. A solution of the ketohydrazine (11 g) and triethylamine hydrochloride (2.2 g, 20% w/w) in xylene 30, (500 ml) was heated at reflux for 3 h. The mixture was cooled to room -temperature and the solvent evaporated in uacuo. The residue was dissolved in dichloromethane, washed with water (x 2), dried (MgS04) and evaporated in vacuo, and the solid recrystallised (dichloromethane/hexane) to give the title-compound (6.8 g, 58%), 1H NMR (360MHz, CDCl3) 8 2.59 (3H, s, Me), 6.90 (1H, s, Ar-H), 7.95 (1H, m, A.r-H), 8.0? (1H, m, Ar-H), 8.34 (1H, m, Ar-H), 8.78.(1H, s, Ar-H); MS (ES+) m/e 286 [MHJ+.
REFERENCE El AMPLE 1 3-(5-Methvlisoxazol-3-vl)-6-(2-nvridyDmethyloxy 1 2 4 triazoloj3 4 aJphthalazine Sodium hydride (244 mg of a 60% dispersion in oil, 6.10 mmol) was added to a stirred solution of 2-pyridylcarbinol (470 mg, 4.27 mmol) in DMF (60 ml) at room temperature under nitrogen and the mixture stirred for 0.25 h. After this time, Intermediate 1 (1160 mg, 4.07 mmol) was added and the mixture stirred for 2h. The solvent was removed in uacuo and the residue dissolved in dichloromethane, washed with water (x2), dried (MgSOa) and evaporated in vacuo. Flash chromatography on silica gel eluting with 3%
methanol/dichloromethane followed by recrystallisation (dichloromethane/hexane) gave the title-product (640 mg, 44%), mp 234 - 236 °C;
'H NMR (360MHz, CDCIs) b 2.59 (3H, d, J =0.8Hz, Me), 5.77 (2H, s, CHz), 6.82 (1H, d, J=0.8Hz, A.r-H), 7.30 (1H, m, Ar-H), 7.74 - 7.85 (3H, m, Ar-H); 7.95 (1H, m, Ar-H), 8.33 (1H, d, J=7.8Hz, Ar-H), 8.64 - 8.72 (2H, m, Ar-H}; MS (ES+) m/e 359 [MHJ+; Anal. Found. C, 62.93; H, 3.56; N, 22.94. CisHi4NsOz 0.05 (CHzCIz) requires C, 63.10; H, 3.92; N, 23.1?%.
6-(6-Bromonvridin-2-vDmethvioxv 3 l5 methvlisoxazol 3 vl) 1 2 4 triazolo(3 4 a] phthalazine The title-compound was prepared from Intermediate 1 and 2-bromopyridine-6-methanol (Tetrahedron Lett., 1996, 50, 2537) following the procedure given for Reference Example I. The product was isolated by addition of water to the reaction mixture and the resulting precipitate was filtered off.
Flash chromatography on silica gel, eluting with ethyl acetate, and recrystallisation (ethyl acetate-methanol) gave the title phthalaxine, mp 247.5 -249 °C; 'H NMR (360 MHz, CDCIs) 8 2.61 (3H, d, J = 0.7 Hz, Me), 5.?3 (2H, s, CHz), 6.82 (1H, d, J = 0.7 Hz, Ar-H), 7.48 (1H, d, J = 7.8 Hz, Ar-H), 7.63 (1H, t, J = 7.7 Hz, Ar-H), ?.76 (1H, d, J = 7.4 Hz, Ar-H), 7.84 (1H, t, J = 8.4 Hz, Ar-H), 7.98 (IH, t, J = 8.4 Hz, Ar-H), 8.31 (1H, d, J = 8.5 Hz, Ar-H), 8.70 (1H, d, Ar-H);
MS (ES+) m/e 437, [MH]+; Anal. Found C, 52.27; H, 2.85; N, 19.14. C19H~3N6O2 -Br. 0.1 (Hz0) requires C, 51.98; H, 3.03; N, 18:60%.
6-Hvdroxv-3-(5-Methvlisoxazol-3-vl)-1 2 4 triazolof3 4 alnhthalaz_ine A solution of sodium hydroxide (0.67 g, I7 mmol) in water (7.5 ml) was added to a stirred solution of Intermediate 1 (1.0 g, 3.5 mmol) in dioxane (37.5 ml) and the mixture heated at reflux for 4 h. The solvent was evaporated in uacuo and the residue partitioned between water and diethyl ether. The aqueous layer was separated, washed with ether (x 1) and then acidified with hydrochloric acid until pH2 was attained. The solid which precipitated out of solution was filtered off and the aqueous filtrate extracted with dichloromethane (x 3). The combined extracts were dried (MgS04) and evaporated in udcuo and combined with the precipitate to give the title product (0.45 g, 48%), 1H NMR
(250 MHz, ds-DMSO) 8 2.58 (3H, d, J = 0.7 Hz, Me), 7.07 (1H, d, J = 0.9 Hz, Ar-H), 7.94 (1H, m, Ar-H), 8.08 (1H, m, Ar-H), 8.24 (1H, d, J = 7.4 Hz, Ar-H), 8.54 (1H, d, J = 7:4 Hz, Ar-H), 13.32 (1H, br s, NH); MS (ES+) mle 268 [MH]+
3-(5-Methvlisoxazol-3-vl)-6-(1H-1 2 3-triazol 5 vDmethyloxy 1 2 4 triazolo f 3.4-alphthalazine a) 5-Formvl-I-f2-(trimethvlsilvbethoxvlmethvl 1 2 3 triazole n-Butyl lithium (6.8m1 of a 1.6M solution in hexanes, 10.9mmo1) was added dropwise over 0.08h to a stirred solution of 1-[2-(trimethyl-silyl)ethoxy]methyl-1,2,3-triazole (J. Heterocycl. Chem., 1992, 29, 1203) (2.077g, 10.42mmo1) in THF (30m1) at -78°C under nitrogen. The solution was allowed to warm to -60°C aver 0.67h, then retooled to -78°C and DMF (0.9m1, 11.6mmo1) added. The mixture was allowed to warm to room temperature and stirred for 16.5h. Saturated ammonium chloride solution (50m1) was added and the _ reaction mixture extracted with diethyl ether (3 x 80m1). The combined ethereal extrants were dried (MgS04), evaporated in uacuo, and the residue chromatographed on silica gel, eluting with 30% ethyl acetate/hexane, to give the WO 99/43677 - 9 _ PCT/GB99/00485 title-triaxole (1.7138, 72%), 1H NMR (360 MHz, CDCIs) 8 0.01 (9H, s, MesSi), 0.92-0.99 (2H, m, CHz), 3.64-3.69 (2H, m, CHz), 6.05 (2H, s, CHa), 8.31 (lH;.s;
Ar-H), 10.12 (1H, s, CHO).
b) 5-Hvdroxvmethvl-1-f2-(trimethvlsilvDethoxvlrnethyl 1 2 3 triazole Sodium borohydride (0.2848, 7.51mmo1) was added to a stirred solution of the preceding triazole (1.7048, 7.495mmol) in methanol (8ml} at 0°C
under nitrogen. The mixture was stirred at 0°C for 0.5h and at room temperature for O.Sh. Water was added and the mixture partitioned between dichloromethane and saturated brine. The aqueous layer was separated and further extracted with dichloromethane (x2). The combined organic layers were dried ((MgS09) and evaporated in uacuo and the residue chromatographed on silica gel, eluting with ?0% ethyl acetate/hexane, to give the title product (1.348, 78%), 1H NMR
(360 MHz, CDCla) 8 0.00 (9H, s, MesSi), 0.90-0.95 (2H, m, CHz), 3.58-3.63 (2H, m, CHz), 4.84 (2H, s, CHz), 5.80 (2H, s, CHz), 7.68 (1H, s, Ar-H).
c) 3-(5-Methvlisoxazol-3-vl)-6-11-f2-(trimethvlsilvDethoxvlmethvl 1 2 3 triazol-5-vllmethvloxv-12 4-triazolof3 4 a]'~n~hthalazine The title-compound was prepared from Intermediate 1 and the preceding alcohol following the procedure described for Example 10, 360 MHz (360 MHz, CDCIs) 8 0.00 (9H, s, MesSi), 0.88-0.93 (2H, m, CHz), 2.63 (3H, s, Me), 3.61-3.66 (2H, m, CHz), 5.92 (2H, s, CHz), 5.97 (2H, s, CHz), 6.89 (1H, s, Ar-H), 7.86 (1H, m, Ar-H), 8.02 (1H, t, J = 7.7 Hz, Ar-H), 8.18 (1H, s, Ar-H), 8.23 (1H, d, J =
8.0 Hz, Ar-H), 8.76 (1H, d, J = 8.0 Hz, Ar-H); MS (ES+) m/e 479 [MH]+.
d) 3-(5-Methvlisoxazol-3-vl)-6-(1H 1 2 3 triazol 5 vbmethyloxv 1 2 4 triazolof3 4-a]nhthalazine A mixture of the preceding product, ethanol (lOml) and 2N HCl (20m1) was heated at 50°C for 15.25h. The solution was basified to pH 12 with saturated sodium carbonate solution and the solvents evaporated in uacuo. The residue was azeotroped with ethanol (x2) and chromatographed on silica gel, eluting with 0-4% methanol/dichloromethane (gradient elution), to give the title product, IH NMR (400 MHz, CDCIs) 8 2.65 (3H, s, Me), 5.73 (2H, s, CHz), 7.02 (1H, s, Ar-H), 7.87 (1H, t, J = 7.8 Hz, Ar-H), 7.99-8.03 (2H, m, 2 of Ar-H), 8.24 (1H, d, J = 8.2 Hz, Ar-H) 8.72 (1H, d, J = 7.9 Hz, Ar-H); MS (ES+) m/e ~~+.
WO 99/43677 - 10 - PCTlGB99/00485 3-(5-Methvlisoxazol-3-vl)-6-ll-methyl-1 2 3 triazol 5 vl)methyloxy 1 2 4 triazolof3 4-alnhthalazine 3-(5-methvlieoxazol 3 vl) 6 (2 methyl 1 2 3 triazol yDmethyloxv-1 2 4-triazolof3 4-alnhthalazine and 3 (5 methylisoxazol 3 vl) 6 (1 methyl-1.2,3-triazol-4-vDmethvloxv-I 2 4-triazolof3 4 aln~hthalazine Lithium hexamethyldisilazide (1.63m1 of a 1M solution in THF, 1.63mmol) was added dropwise to a stirred solution of 3-(5-methylisoxazol-3-yl)-6-(1H-1,2,3-triazol-5-yl)methyloxy-1,2,4-triazolo[3,4-a]phthalazine (241mg, 0.626mmo1) prepared as in Reference Example 3 in DMF (50m1) at -31°C
under nitrogen. The mixture was warmed to -23°C over 1.5h, methyl iodide (O.lOml, l.6mmo1) added dropwise and the reaction mixture allowed to warm to room temperature overnight. Water was added and the solvent evaporated in vacuo.
The residue was partitioned between dichloromethane and water and the aqueous phase separated and re-extracted with dichloromethane (xl). The combined organic extrants were washed with brine (xl), dried (MgS04) and evaporated in vacuo . Chromatography of the residue on silica gel, eluting with 0-5% methanol/dichloromethane (gradient elution), followed by preparative HPLC (YMC Sil column, 250 x 20mm) eluting with 5% methanol/1-chlorobutane, separated the triazole isomers:
Least polar isomer (HPLC solvent system): 3-(5-methvlisoxazol-3-yD-6-(2-methvl-12 3-triazol-4-vl)methvloxv 12 4 triazolo[3 4 a]phthalazine 1H NMR
(400 MHz, CDCIa) 8 2.59 (3H, s, Me), 4.21 (3H, s, Me), 5.73 (2H, s, CHz), 6.89 (1H, s, Ar-H), 7.79 (1H, m, Ar-H), 7.94 (1H, m, Ar-H), 8.10 (1H, s, Ar-H), 8.22 (1H, d, J = 8.0 Hz, Ar-H), 8.67 (1H, d, J = 8.0 Hz, Ar-H); MS (ES+) mle 363 [MH]+.
Intermediate polarity isomer: 3-l5-methvlisoxazol-3-vD-6-(1-methyl 1 2 3 triazol 4-vl)methvloxv-1 2 4-triazolof3 4-alDhthalazine 1H NMR (400MHz, CDCls) 8 2.60 (3H, s, Me), 4.09 (3H, s, Me), 5.78 (2H, s, CHz), 6.90 (1H, d, J = 0.8 Hz, Ar-H), 7.80 (1H, m, Ar-H), 7.94 (1H, m, Ar-H), 8.25 (1H, d, J = 8.0 Hz, Ar-H), 8.65 (1H, d, J = 8.0 Hz, Ar-H), 8.73 (1H, s, Ar-H); MS (ES+) mle 363 [MH]+.
Most polar isomer (HPLC solvent system): 3-(5-methvlisoxazol-3-vl)-6-(1-methv_1-1.2.3-triazol-5-vl)methvloxy-1 2 4-triazolof3 4 alnhthalazine 1H NMR (400 MHz, CDCIa) 8 2.56 (3H, s, Me), 4.19 (3H, s, Me), 5.?6 (2H, s, CHz), 6.82 (1H, s, Ar-H), 7.80 (1H, m, Ar-H), 7.96 (1H, m, Ar-H), 8.04 (1H, s, Ar-H), 8.12 (1H, d, J = 8.8 Hz, Ar-H), 8.67 (1H, d, J = 8.0 Hz, Ar-H); MS (ES+) m/e 363 [MIi]+. _ _
Claims (5)
1. 3-(5-Methylisoxazol-3-yl)-6-(1-methyl-1,2,3-triazol-4-yl)methyloxy-1,2,4-triazolo[3,4-a]phthalazine.
2. A pharmaceutical composition comprising the compound as described in claim 1 and a pharmaceutically acceptable carrier.
3. 3-(5-Methylisoxazol-3-yl)-6-(1-methyl-1,2,3-triazol-4-yl)methyloxy-1,2,4-triazolo[3,4-a]phthalazine for use in a method of treatment of the human or animal body.
4. The use of the compound of claim 1 for the manufacture of a medicament for the enhancement of cognition.
5. A method of enhancing cognition in a subject suffering from diminished cognition which comprises administering to that subject a cognition enhancing amount of the compound of claim 1.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9803992.8A GB9803992D0 (en) | 1998-02-25 | 1998-02-25 | Therapeutic agents |
GB9803992.8 | 1998-02-25 | ||
WOPCT/GB98/01307 | 1998-05-06 | ||
PCT/GB1998/001307 WO1998050385A1 (en) | 1997-05-08 | 1998-05-06 | SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS |
GB9824896.6 | 1998-11-12 | ||
GBGB9824896.6A GB9824896D0 (en) | 1998-11-12 | 1998-11-12 | Therapeutic compound |
PCT/GB1999/000485 WO1999043677A1 (en) | 1998-02-25 | 1999-02-17 | SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PYRIDAZINE |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2317416A1 true CA2317416A1 (en) | 1999-09-02 |
Family
ID=27269184
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002317416A Abandoned CA2317416A1 (en) | 1998-02-25 | 1999-02-17 | Substituted 1,2,4-triazolo[3,4-a]pyridazine |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1070066A1 (en) |
JP (1) | JP2002504554A (en) |
CN (1) | CN1291194A (en) |
AU (1) | AU746719B2 (en) |
BG (1) | BG104705A (en) |
CA (1) | CA2317416A1 (en) |
EA (1) | EA002824B1 (en) |
HR (1) | HRP20000555A2 (en) |
HU (1) | HUP0100647A3 (en) |
NZ (1) | NZ505695A (en) |
PL (1) | PL341975A1 (en) |
SK (1) | SK12772000A3 (en) |
TR (1) | TR200002469T2 (en) |
WO (1) | WO1999043677A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9821179D0 (en) * | 1998-09-30 | 1998-11-25 | Merck Sharp & Dohme | Therapeutic use |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI81350C (en) * | 1982-01-18 | 1990-10-10 | Lepetit Spa | ANALOGFOERFARANDE FOER FRAMSTAELLNING AV NYA, FARMAKOLOGISKT AKTIVA 6-SUBSTITUERADE S-TRIATSOLO / 3,4-A / PTHALAZINDERIVAT. |
AU724076B2 (en) * | 1996-07-25 | 2000-09-14 | Merck Sharp & Dohme Limited | Substituted triazolo pyridazine derivatives as inverse agonists of the GABAAalpha5 receptor subtype |
WO1998050385A1 (en) * | 1997-05-08 | 1998-11-12 | Merck Sharp & Dohme Limited | SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS |
-
1999
- 1999-02-17 CA CA002317416A patent/CA2317416A1/en not_active Abandoned
- 1999-02-17 PL PL99341975A patent/PL341975A1/en not_active Application Discontinuation
- 1999-02-17 HU HU0100647A patent/HUP0100647A3/en unknown
- 1999-02-17 TR TR2000/02469T patent/TR200002469T2/en unknown
- 1999-02-17 SK SK1277-2000A patent/SK12772000A3/en unknown
- 1999-02-17 EA EA200000878A patent/EA002824B1/en not_active IP Right Cessation
- 1999-02-17 JP JP2000533432A patent/JP2002504554A/en not_active Withdrawn
- 1999-02-17 WO PCT/GB1999/000485 patent/WO1999043677A1/en not_active Application Discontinuation
- 1999-02-17 CN CN99803190A patent/CN1291194A/en active Pending
- 1999-02-17 AU AU25368/99A patent/AU746719B2/en not_active Ceased
- 1999-02-17 EP EP99905069A patent/EP1070066A1/en not_active Withdrawn
- 1999-02-17 NZ NZ505695A patent/NZ505695A/en unknown
-
2000
- 2000-08-22 BG BG104705A patent/BG104705A/en unknown
- 2000-08-25 HR HR20000555A patent/HRP20000555A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EA200000878A1 (en) | 2001-02-26 |
TR200002469T2 (en) | 2000-12-21 |
AU746719B2 (en) | 2002-05-02 |
PL341975A1 (en) | 2001-05-07 |
WO1999043677A1 (en) | 1999-09-02 |
HUP0100647A2 (en) | 2001-09-28 |
HRP20000555A2 (en) | 2001-08-31 |
NZ505695A (en) | 2002-03-01 |
SK12772000A3 (en) | 2001-03-12 |
CN1291194A (en) | 2001-04-11 |
HUP0100647A3 (en) | 2003-03-28 |
JP2002504554A (en) | 2002-02-12 |
EA002824B1 (en) | 2002-10-31 |
AU2536899A (en) | 1999-09-15 |
EP1070066A1 (en) | 2001-01-24 |
BG104705A (en) | 2001-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6500828B1 (en) | Triazolo-pyridazine derivatives as ligands for gaba receptors | |
EP0986562A1 (en) | Substituted 1,2,4-triazolo 3,4-a]phthalazine derivatives as gaba alpha 5 ligands | |
US6313125B1 (en) | Therapeutically active 1,2,4-triazolo[4.,3-B] pyridazine derivatives as ligands for GABA receptors | |
CZ290883B6 (en) | Triazolopyridazine derivatives, process of their preparation and pharmaceutical preparation in which the derivatives are comprised | |
CA2468893A1 (en) | Imidazopyridines, pyrimidines and triazines for enhancing cognition as gaba-a alpha 5 receptor subtype ligands | |
AU613125B2 (en) | Imidazoquinoxaline compounds and their preparation and use | |
US20040043982A1 (en) | Nitrogen substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives for enhancing cognition | |
US6949549B2 (en) | Imidazolophthalazine derivatives as ligands for GABAA receptors | |
US6297235B1 (en) | Triazolopyridazine derivatives for treating anxiety and enhancing cognition | |
JP2003516994A (en) | Substituted 1,2,3-triazolo [1,5-a] quinazolines for improving cognitive ability | |
US6448249B1 (en) | Substituted 1,2,4-triazolo[3,4-A]phthalazine derivatives as GABAα5 ligands | |
AU746719B2 (en) | Substituted 1,2,4-triazolo(3,4-a)pyridazine | |
US6613766B1 (en) | Pentaaza-cyclopental[a]naphthalene derivatives as ligands for GABAa α5 receptors | |
CA2362400A1 (en) | Triazolo-pyridazine derivatives as ligands for gaba receptors | |
US6444666B1 (en) | Triazolopyridazine Derivatives for treating anxiety and enhancing cognition | |
US6946461B2 (en) | Imidazolophthalazine derivatives as ligands for GABAA receptors | |
MXPA00008320A (en) | SUBSTITUTED 1,2,4-TRIAZOLO[3,4-a]PYRIDAZINE | |
HRP980584A2 (en) | SUBSTITUTED 1,2,4-TRIAZOLO/3,4-a/ PHTHALAZINE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |